ZBIO — Zenas BioPharma Inc. price, chart and key statistics

Price data

Price

$28.18

YTD price return

-22.39%

YTD total return

-22.39%

Market cap

1.8B2024-09 707.1M2026-10 1.8B+159.7% over the window

Enterprise value

1.2B

Shares outstanding

65.2M2023-12 1.6M2026-06 65.2M+4033.3% over the window

52W low

$13.50

52W high

$44.60

From 52W high

-36.82%

From 52W low

+108.74%

52W range

47%

Volume

Rel volume

0.79×

30D volume

689.3K

30D $ vol

19.9M

Fundamentals

Sales (ttm)

1M2023-12 50M2026-06 1M-98.0% over the window

Sales/share

$0.022023-12 $31.712026-06 $0.02-100.0% over the window

EPS (ttm)

-$9.052023-12 -$24.252026-06 -$9.05-62.7% over the window

FCF (ttm)

-226M2023-12 -30.5M2026-06 -226M+639.8% over the window

FCF/share

-$3.472023-12 -$19.372026-06 -$3.47-82.1% over the window

Book value/share

$3.792023-12 -$143.152026-06 $3.79-102.6% over the window

Net margin

-48438.40%2023-12 -74.2%2026-06 -48438.4%+65138.7% over the window

ROE

-196.03%2024-12 -50.2%2026-06 -196.0%+290.2% over the window

ROA

-69.03%2023-12 -54.4%2026-06 -69.0%+26.8% over the window

Debt / equity

0.32×

Current ratio

9.932023-12 2.572026-06 9.93+286.3% over the window

Growth (CAGR, ttm) · 10Y

Sales

-93.35%2025-06-30 → 2026-06-3015M → 1M (-93.3% total)-79.13%2023-12-31 → 2026-06-3050M → 1M (-98.0% total)n/an/a

Shares

+54.82%2025-06-30 → 2026-06-3042.1M → 65.2M (+54.8% total)+343.93%2023-12-31 → 2026-06-301.6M → 65.2M (+4033.3% total)n/an/a

Per-share growth (CAGR, ttm) · 10Y

Sales/share

-95.70%2025-06-30 → 2026-06-30$0.36 → $0.02 (-95.7% total)-95.30%2023-12-31 → 2026-06-30$31.71 → $0.02 (-100.0% total)n/an/a

Book value/share

-33.39%2025-06-30 → 2026-06-30$5.69 → $3.79 (-33.4% total)n/an/an/a

Price

+7.77%2025-10-20 → 2026-10-20$26.15 → $28.18 (+7.8% total)Price appreciation from split-adjusted daily closes, excluding dividends; endpoints are exact trading-day anniversaries of the latest close.n/an/an/a

Total return

+7.77%2025-10-20 → 2026-10-20$26.15 → $28.18 (+7.8% total)Total return with dividends reinvested (adjusted daily closes); endpoints are exact trading-day anniversaries of the latest close. The gap against the Price row is the dividend contribution.n/an/an/a

Fundamentals end at the last reported quarter; price and total return end at the latest close.

Valuation

P/E (ttm)Price ÷ TTM diluted EPS. Net income carries everything below the operating line, including one-off gains. Negative when the trailing year lost money.

-3.1×2024-09 -19.052026-10 -3.79-80.1% over the window

Fwd P/E

-6.1×

P/S (ttm)Market cap ÷ TTM revenue.

1836.7×2024-09 14.142026-10 1836.68+12887.3% over the window

P/B (mrq)Market cap ÷ stockholders' equity at the most recent quarter end.

7.4×2024-09 1.972026-10 7.43+277.8% over the window

EV/Sales (ttm)

1242.7×

FCF yield (ttm)TTM free cash flow ÷ market cap — the inverse of P/FCF.

-12.30%2024-12 -35.0%2026-06 -13.7%-61.0% over the window

Buyback yield (realized, 1y)1 − shares_at(2026-06-30) ÷ shares_at(2025-06-30) = 1 − 65.2M ÷ 42.1M. Point-in-time share counts from the company's own SEC filings (the same count at both ends), published only when the cash flow statement shows repurchases inside that window. A falling price can't inflate it; negative means net dilution.

-54.82%

Shareholder yield (realized, 1y)Buyback leg + dividend leg: shares retired over the year (-54.82%) + dividends paid over that year ($0) ÷ market_cap_at(2025-06-30) ($408M). Both legs are measured against the start of the window, so a payout can't shrink its own denominator.

-54.82%

Buyback yield (cash, ttm)Buybacks net of issuance over the trailing twelve months ($0) ÷ today's market cap ($1.8B). Dollars SPENT over what the company is worth NOW — a stock that fell after buying reads high.

0.00%2024-12 0.0%2026-06 0.0%

Shareholder yield (cash, ttm)(TTM buybacks net of issuance $0 + TTM dividends $0) ÷ today's market cap ($1.8B). Same caveat as the cash buyback yield.

0.00%2024-12 0.0%2026-06 0.0%